title: Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates.
abstract: Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (PB) (positive blood cultures after ≥7 days of therapy) represents a clinically challenging subset of invasive MRSA infections. In this investigation, we examined the potential correlation of specific virulence signatures with PB versus resolving MRSA bacteremia (RB) (negative blood cultures within 2 to 4 days of therapy) strains. Thirty-six MRSA isolates from patients enrolled in a recent multinational clinical trial were studied for (i) susceptibility to host defense cationic peptides (HDPs) (i.e., thrombin-induced platelet microbicidal proteins [tPMPs] and human neutrophil peptide 1 [hNP-1]); (ii) adherence to host endovascular ligands (fibronectin) and cells (endothelial cells); and (iii) biofilm formation. We found that PB isolates exhibited significantly reduced susceptibilities to tPMPs and hNP-1 (P < 0.001 and P = 0.023, respectively). There was no significant association between the PB outcome and fibronectin binding, endothelial cell binding, or biofilm formation (P = 0.25, 0.97, and 0.064 versus RB strains, respectively). However, multiple logistic regression analysis revealed that the PB outcome was significantly associated with the combination of reduced susceptibilities to HDPs and extent of biofilm formation (P < 0.0001). Similar results were obtained in a second analysis using days of bacteremia as a continuous outcome, showing that reduced HDP susceptibilities and increased biofilm formation cocontributed to predict the duration of bacteremia. Our data indicate that PB isolates have specific pathogenic signatures independent of conventional antimicrobial susceptibility. These combinatorial mosaics can be defined and used to prospectively distinguish PB from RB strains in advance and potentially to predict ultimate clinical outcomes.
authors.affiliation: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
authors.forename: Kati
authors.initials: K
authors.lastname: Seidl
authors.forename: Arnold S
authors.initials: AS
authors.lastname: Bayer
authors.forename: Vance G
authors.initials: VG
authors.lastname: Fowler
authors.forename: James A
authors.initials: JA
authors.lastname: McKinnell
authors.forename: Wessam
authors.initials: W
authors.lastname: Abdel Hady
authors.forename: George
authors.initials: G
authors.lastname: Sakoulas
authors.forename: Michael R
authors.initials: MR
authors.lastname: Yeaman
authors.forename: Yan Q
authors.initials: YQ
authors.lastname: Xiong
mesh_terms: D016470:Bacteremia / Q000276:immunology* / Q000382:microbiology*; D001422:Bacterial Adhesion; D015373:Bacterial Typing Techniques; D018441:Biofilms / Q000254:growth & development; D001769:Blood / Q000382:microbiology; D003470:Culture Media; D042783:Endothelial Cells / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000145:classification* / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity*; D008826:Microbial Sensitivity Tests; D010641:Phenotype; D013203:Staphylococcal Infections / Q000276:immunology / Q000382:microbiology; D014774:Virulence; D023084:alpha-Defensins / Q000494:pharmacology; D001620:beta-Thromboglobulin / Q000494:pharmacology*
chemical_list: D003470:Culture Media; D005353:Fibronectins; C061615:PPBP protein, human; D023084:alpha-Defensins; D001620:beta-Thromboglobulin; C406413:human neutrophil peptide 1